Effects of lipodystrophy on quality of life and depression in HIV-infected men on HAART

AIDS Patient Care and STDs

Volumn 20, Issue 8, 2006, Pages 565-575

  Steel, Jennifer ^a   Landsittel, D ^c   Calhoun, B ^c   Wieand, S ^b   Kingsley, L A ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c Dusquene School of Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; ARTICLE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SHORT FORM 36; SYMPTOMATOLOGY; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; HIV ASSOCIATED LIPODYSTROPHY; HOMOSEXUALITY; MIDDLE AGED; PREVALENCE; PSYCHOLOGICAL ASPECT; STATISTICAL MODEL; STATISTICS; UNITED STATES;

ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; DEPRESSION; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HOMOSEXUALITY, MALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PENNSYLVANIA; PREVALENCE; PROSPECTIVE STUDIES; QUALITY OF LIFE;

EID: 33748854814     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2006.20.565     Document Type: Article

References (26)

1. Mauss S, Corzillius M, Wolf E, et al. Risk factors for the HIV associated lipodystrophy syndrome in patients with homogenous duration of ART. Presented at the 2002 International Conference on AIDS, Barcelona, Spain: July 7-12, 2002.
2. Hadigan C, Meigs J, Corcoran C, et al. Characterization of metabolic abnormalities and coronary artery disease risk factors in HIBV-infected men and women with lipodystrophy. Presented at the 2000 International AIDS Conference, Durban, South Africa: July 9-14, 2000.
3. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LOPOCO study. AIDS 2000;14:37-49.
4. Lenert LA, Feddersen M, Sturley A, Lee D. Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. Am J Med 2002;113:229-232.
5. Petti R, Muurahainen N, Falutz J, et al. HIV-related truncal obesity: A comparison of physician and patient diagnoses in the SALSA (self-ascertained lipodystrophy syndrome assessment) questionnaires. Presented at the 1999 Conference of Retrovirus and Opportunistic Infection, Chicago, IL: January 31-February 4, 1999.
6. Kingsley L. Body habitus changes in HIV-associated lipodystrophy syndrome (HIV-LS). 2001 Sessions of the International Association of Physicians in AIDS Care.
7. Tien P, Cole S, Williams C, Li R, et al. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr 2003;34:461-466.
8. Dieterich D, Aymat R, Braun J, et al. Incidence of body habitus changes in a cohort of 725 HIV-infected patients. Presented at the Conference on Retroviruses and Opportunistic Infection, Chicago, IL: January 31-February 4, 1999.
9. Torres R, Cadman J, Kassous J, Maroldo L, Unger K. Long-term follow-up of patients with HARS receiving rhGH: Another dilemma of early versus delayed intervention. Presented at the 2000 International AIDS Conference, Durban, South Africa: July 9-14, 2000.
10. Kotler DP, Grunfeld C, Murrahainen N, Wanke C, Thomspson M. Low dose maintenance therapy with recombinant human growth factor sustains effects of previous r-hGH treatment in HIV+ patients center fat: Treatment results at 60 weeks. Presented at the 11th Conference on Retroviruses and Opportunistic Infections. Moscone West, San Francisco, February 8-11, 2004.
11. Cotton F. Switching protease inhibitor (PI) to nevirapine (NVP) leads to reversal of hyperlipidemia and lipodystrophy. Presented at the 2000 International AIDS Conference, Durban, South Africa: July 9-14, 2000.
12. Fisac C, Fumero E, Crespo M, et al. Metabolic changes in patients switching from a protease inhibitor regimen to abacavir, efavirenz, or nevirapine: 24-month randomized study. Presented at the 11th Conference on Retroviruses and Opportunistic Infections. Moscone West, San Francisco, CA: February 8-11, 2004.
13. Hoy JF, Gahan ME, Carr A, et al. Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir. J Infect Dis 2004;190:688-692.
14. Falutz J. Update on HIV/HAART associated morphologic and metabolic abnormalities. Forum Nutr 2003;56:158-162 .
15. Goetzenich A, Corzillius M, Mauss S, et al. Impact of lipodystrophy on quality of life. Presented at the 2000 International AIDS Conference, Durban, South Africa: July 9-14, 2000.
16. Blanch J, Rousaud A, Martinez E, et al. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis 2004;38:1464-1470.
17. Nicholas PK, Kirksey KM, Corless IB, Kemppainen J. Lipodystrophy and quality of life in HIV symptoms management issues. Appl Nurs Res 2005;18:55-58.
18. Oette M, Juretzko P, Kroidi A, et al. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-seropositive patients. AIDS Patient Care Stds 2002;16:413-417.
19. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Arch Intern Med 2000;160:2050-2056.
20. Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr. The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987;126:310-318.
21. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, 1993.
22. Ware JE. The SF-36 Health survey. In Spiker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1996:337-345.
23. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Meas 1997;1:385-401.
24. Radloff LS. The use of the Center for Epidemiological Studies Depression Scale in adolescents and young adults. J Youth Adolesc 1991;20:149-166.
25. Dukers NH, Stolte IG, Albrect N, Coutinho RA, deWit JB. The impact of experiencing lipodystrophy on sexual behavior and well-being among HIV-infected homosexual men. AIDS 2001;15:812-813.
26. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment center. AIDS 2001;15:191-194.